Experiments conducted on worms, zebrafish, mice and, finally, on human subjects in a limited clinical trial conclude that pimozide may be effective in treating what’s known as “Lou Gehrig’s disease.”
Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medication that could make it possible to treat individuals with amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease.
An article published today in JCI Insight concludes that pimozide was found to be safe and over the short term, preliminary data shows that it could stabilize the progression of ALS. This neurodegenerative disease normally leads to a progressive paralysis of the skeletal muscles and, on average, three years after the onset of symptoms, to death.
“This medication alleviates the symptoms of ALS in animal models,” said Alex Parker, a CRCHUM researcher and professor at Université de Montréal. “Riluzole and edaravone, the drugs currently used, have modest effects. Other studies must be conducted to confirm our results, but we believe that we’ve found a medication that may prove to be more effective in improving patients’ quality of life.”
FROM WORM TO MAN
The story behind the discovery began six years ago with a little millimeter-long nematode worm called C. elegans. In his laboratory, Parker genetically modified the worms so that they would exhibit aspects of the human form of ALS. Simultaneously, his colleague Pierre Drapeau did the same thing to another animal, the zebrafish, a tiny tropical fish only 5 centimetres long.
The two scientists obtained funding from the U.S. Department of Defense to test medications on these worms and fish born with ALS. “We sifted through a library of 3,850 molecules approved for the treatment of other diseases, and found a class of antipsychotic drugs that stabilize mobility in worms and fish,” said Drapeau, a CRCHUM researcher, professor at Université de Montréal and principal investigator on the study. “Pimozide works especially well in preventing paralysis in fish by preserving the neuromuscular junction.”
Subsequently, Université de Montréal Professor Richard Robitaille performed electrophysiological tests on mice in his laboratory and reached the same conclusion. Thus, pimozide was shown to maintain neuromuscular function in three different animal models: worms, fish and mice.
At the annual ALS Canada Research Forum in 2012, the researchers met Dr. Lawrence Korngut, an Associate Professor at the CSM, member of the Hotchkiss Brain Institute (HBI) and Director of the Calgary ALS/Motor Neuron Disease Clinic. “Pimozide is a drug that has been well-known for 50 years,” the neurologist said. “It was approved for treating certain types of psychiatric conditions, like schizophrenia, and costs only 9 cents per pill. Other recent studies have shown genetic links between schizophrenia and ALS. The next logical step was to test it on human volunteers with ALS.”
In 2015, the first preclinical trial for ALS was launched in Canada with a small group of 25 patients who had ALS. Funding was provided by the Quirk family of Calgary, by the HBI, and the Clinical Research Unit at UCalgary.
“We found the highest dose most likely to be tolerated in individuals with ALS – a lower dose than that used in other conditions – and we have preliminary proof showing that pimozide may be useful,” said Korngut.
The initial clinical trial was modest in scope. But after only six weeks, the researchers had a first indication of the drug’s efficacy. Loss of control of the thenar muscles, located in the palm of the hand between thumb and index finger, is usually one of the first signs of ALS. For patients who took pimozide, this function remained stable. This observation is tempered by the very limited size and length of the clinical trial.
“For us, this is an indication that we found the right therapeutic target,” said Drapeau. “Pimozide acts directly on the neuromuscular junction, as shown in our animal models. We don’t yet know whether pimozide has a curative effect, or whether it only preserves normal neuromuscular function to at least stabilize the disease. This is also the first time that a potential drug for human patients was discovered based on basic research on small organisms such as worms and fish.”
Now comes the next step: a phase II clinical trial on 100 volunteers, funded by the “The Ice Bucket Challenge” through a partnership between ALS Canada and Brain Canada to begin in the next few weeks. Headed by Korngut in Calgary and conducted in nine hospital centres across Canada, the study aims to confirm that pimozide is safe and to measure, over a six-month period, its effect on the progression of the disease and its symptoms and on patients’ quality of life.
Daniel Rompré, 47, father of two teenage girls, hopes to participate in the new study. He was diagnosed with ALS in March 2016. The muscles of his upper body are getting weaker, he is beginning to have trouble speaking, and he can no longer use his left arm. “It is hard to maintain a positive outlook,” Rompré said. “You ask yourself: ‘Why me?’ But at least it’s encouraging to see that research is advancing. There has been more progress in the last five years than in 100 years of research on the disease.”
It is too soon to draw firm conclusions about the safety and efficacy of pimozide. “At this stage, people with ALS should not use this medication,” Korngut emphasized. “We must first confirm that it is really useful and safe in the longer term. It is also important to be aware that pimozide is associated with significant side effects. Therefore, it should only be prescribed in the context of a research study.”
The Latest on: Lou Gehrig’s disease
- WALSH, WILLIAM R., III (Bill/Coach)on November 18, 2019 at 8:00 pm
III (Bill/Coach), - 52, of Galloway, passed away peacefully on November 15, 2019, at his home in Galloway, NJ, surrounded by loved ones. Bill fought ALS, Lou Gehrig's disease valiantly for almost 3 ...
- Former Holy Spirit football coach Bill Walsh dies after long battle with ALSon November 15, 2019 at 1:39 pm
A 1985 graduate and head football coach from 2003-2007, Walsh died after battling Lou Gehrig's disease - amyotrophic lateral sclerosis, known more as ALS. He was diagnosed in early 2016. "The ...
- Genius Fund Looking To Improve ALS Treatments, Holding First Event At Franklin Instituteon November 13, 2019 at 3:35 pm
PHILADELPHIA (CBS) — There’s new help in the fight against ALS. A Genius Fund, started here in Philadelphia, is aimed at research looking for better treatments for the disease also known as Lou Gehrig ...
- ALS walkers support fight against Lou Gehrig's diseaseon November 13, 2019 at 11:00 am
The Louisiana-Mississippi chapter of the ALS Association held a Walk to Defeat ALS on Nov. 2 at the Pennington Biomedical Research Center in Baton Rouge. ALS, or amyotrophic lateral sclerosis, is also ...
- Doctor with terminal motor neurone disease completes his transition into 'world's first cyborg'on November 13, 2019 at 4:12 am
As well as being known as ALS and Charcot's disease, MND is frequently referred to as Lou Gehrig's disease. Lou Gehrig was a hugely popular baseball player, who played for the New York Yankees between ...
- 'ALS is a monster': Two men with debilitating Lou Gehrig's disease use prayer to cope with diagnosison November 12, 2019 at 2:56 pm
AND HOW THEY JUST MIGHT LEAD TO THAT CURE. REPORTING IN DURHA Two men who are suffering the debilitating symptoms of ALS are praying for a cure. Commonly known as Lou Gehrig's disease, amyotrophic ...
- Column: The hard lessons of losson November 12, 2019 at 1:00 am
Over the course of a year, he had experienced a progressive weakness and shortness of breath. He lost a lot of weight. There was no diagnosis until Aug. 28, when we learned that he had ALS, Lou Gehrig ...
- Ex-NFL star Eric Stevens vs. ALS: ‘Our battle right now is fighting for my life’on November 11, 2019 at 3:00 pm
But he has hope. Eric Stevens is a firefighter and former Cal football player who has recently been diagnosed with ALS, the rare neurodegenerative disease that affects nerve cells in the brain and the ...
- What To Know About Medicare Insurance Plans For Newly Retired Seniorson November 11, 2019 at 8:54 am
It primarily covers people who are aged 65 or older. Nonetheless, younger adults with disabilities and those with End-Stage Renal Disease as well as amyotrophic lateral sclerosis (ALS), which is also ...
- Warminster softball player striking out ALSon November 9, 2019 at 5:15 am
Her coach, Greg Heydet of Warwick, has amyotrophic lateral sclerosis or ALS, also called Lou Gehrig’s Disease. It destroys the ability of nerves to transmit motor signals to muscles making them move.
via Google News and Bing News